CHM chimeric therapeutics limited

good points VA.if people look passed the share price, there is...

  1. 298 Posts.
    lightbulb Created with Sketch. 92
    good points VA.

    if people look passed the share price, there is tantalising value with just their lead asset CDH17:
    - world first 3rd Gen CART
    - CART developed by the pioneers of CART at UPenn
    - compelling preclinical data against 7 GI cancer lines
    - GI cancer market alone is worth US$25bn per annum
    - very exciting early signals of efficacy with 100% disease control rate at the lowest dosage level
    - scans and blood tests are showing a text book response with excellent expansion and persistence
    - potential signs that patient 2 may move from stable disease to partial response
    - enquiries from other cell therapy companies
    - relative performance of CHM therapy compared to claudin 18.2 second Gen cart (which has been described as a blockbuster) may be better based on persistence of CART


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.3¢
Change
-0.001(25.0%)
Mkt cap ! $9.747M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $11.33K 3.775M

Buyers (Bids)

No. Vol. Price($)
75 71644408 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 87927011 26
View Market Depth
Last trade - 14.48pm 31/07/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.